<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 03 Mar 2021 07:55:24 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>小药谈靶点：Claudin18.2</title><link>https://mp.weixin.qq.com/s/Cf5QTMSH2fD4H9AST0EnfQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfHFd07ElgPQibS5q8LqNhZzvQkmap98q5E7RZEPQL9z4T45XaGMgXNQQKY5Sr4KDqYYqNbVL8aejfw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>CLDN18.2在HER-2阴性胃癌患者中是一个很有前途的靶点]]></content:encoded><pubDate>Wed, 03 Mar 2021 06:18:59 +0800</pubDate></item><item><title>小药谈靶点：BCMA</title><link>https://mp.weixin.qq.com/s/ktOOvHwLm0zGXtddhZz_Ww</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfHFd07ElgPQibS5q8LqNhZzvONwvicNlkaiaTp2I5cwBQhXfA9VM4xEfMOm9c1w3DGqB8XOWZKLbblZg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>BCMA在多发性骨髓瘤中将继续扮演一个重要角色]]></content:encoded><pubDate>Wed, 03 Mar 2021 06:18:59 +0800</pubDate></item><item><title>小药谈靶点：LILRB4</title><link>https://mp.weixin.qq.com/s/JhH617eRh2ywsIpDk_pf1A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwRAqmvQicwE7nLl6BsLqYibHhlQm0BAXtM94Ilbng2U5jeiaPMLp6TcjfSjibSYe1hDnBegZibJ2jXEfXg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>LILRB4是治疗急性髓系细胞白血病的重要靶点]]></content:encoded><pubDate>Wed, 03 Mar 2021 06:18:59 +0800</pubDate></item><item><title>小药谈靶点：MET</title><link>https://mp.weixin.qq.com/s/YMThqphDzgg0WMtHiRZt6g</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwTcQtVsichPgia92SnYuYXps58uico1WfsicUpMPtZ9Dibg3xw7xvibxVru0EJeC3IEtvuApOWoZgaE33LA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>HGF/MET驱动的信号是肿瘤侵袭转移和耐药的基础]]></content:encoded><pubDate>Wed, 03 Mar 2021 06:18:59 +0800</pubDate></item><item><title>小药谈靶点：IL2和IL15</title><link>https://mp.weixin.qq.com/s/m0mWq6GFiqdqAY52BU7e0Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfHFd07ElgPQibS5q8LqNhZzvRVkWW3dCLMtia2WsmAbsZAtVo9MhaLGxeflvAWuSkXyd7nOSpJR5jXg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>基于IL-2和IL-15在体内扩增和激活效应淋巴细胞的能力，它们的治疗潜力正在不断被开发。]]></content:encoded><pubDate>Wed, 03 Mar 2021 06:18:59 +0800</pubDate></item><item><title>小药谈靶点：neuronilin-1</title><link>https://mp.weixin.qq.com/s/eSrbo0Rmy9NV99AaRD9K9g</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfHFd07ElgPQibS5q8LqNhZzvYyq50F2rLbgicmlzO8aewIibjM4BERmSaOdjNV94SFgOpNwryPgAic24g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>NRP1在TME中作为一个关键的免疫调节剂具有诱人的开发前景。]]></content:encoded><pubDate>Wed, 03 Mar 2021 06:18:59 +0800</pubDate></item><item><title>小药谈靶点：TREM2</title><link>https://mp.weixin.qq.com/s/mFkcW5PJCBZ0b_uQgZ5YYA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwRQq2Dh2Ih9vFiaaksr9slQMCKk34SQCEnGNgEXCibrYstUAGBriaJwLFicCcd7MAsXHdyvj0vufGtgVA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>TREM2在各种疾病中成为一个中心组织损伤信号中枢]]></content:encoded><pubDate>Wed, 03 Mar 2021 06:18:59 +0800</pubDate></item><item><title>小药谈靶点：BTN3A1</title><link>https://mp.weixin.qq.com/s/lXn5cnk0akIkWQ4vqsaFMw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfHFd07ElgPQibS5q8LqNhZzvbB9QUshU9yicLaeDQibyZ0HMpBCPuSWsSeCWKjQAHcRCsiatO0PwbxqWA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>BTN3A1通过协调αβ和γδ-T细胞活性调控抗肿瘤反应]]></content:encoded><pubDate>Wed, 03 Mar 2021 06:18:59 +0800</pubDate></item><item><title>小药谈ICI：TIGIT</title><link>https://mp.weixin.qq.com/s/FMUf4SN1s4h3qoBaMTmjmw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfEp9uphkA8dTZeETrGbGwUNxL3ta6RCdVMW3WhGe6s5Fnsx6sn94w53vQ1mkkNDurrOAPxd4uUgNw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>PD-1和TIGIT双重阻断剂是一种很有前途的肿瘤联合免疫治疗方法。]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：lAG-3</title><link>https://mp.weixin.qq.com/s/khkOmFLQbjTU_bYDmGzD6A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfEp9uphkA8dTZeETrGbGwUNaoeXICzfZMUrg1QxFJ7sjUajI35HHGSic8EK5prnk97CA9WIlRUb0RQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>LAG-3作为新一代发现的抑制性检查点，有望成为肿瘤治疗中极具前景的靶点。]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：TIMs，TAMs和PS</title><link>https://mp.weixin.qq.com/s/E3YULQbIuGuiSFAnsb-Sxw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfEp9uphkA8dTZeETrGbGwUNxL3ta6RCdVMW3WhGe6s5Fnsx6sn94w53vQ1mkkNDurrOAPxd4uUgNw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>PD-1和TIGIT双重阻断剂是一种很有前途的肿瘤联合免疫治疗方法。]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：VISTA</title><link>https://mp.weixin.qq.com/s/FbhQjT6RoyT-5FXmsKNelQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwS2CiaHn4zWQ7v7Qjxyb46Ampicct4MGp4BibFib5xd53G5gJ9r8OKIyZTC9Cxd0lUJUjxJCm9Mea1DCw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>VISTA可以独立于PD-1/和CTLA-4等免疫检查点发挥免疫抑制作用。]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：B7-H3</title><link>https://mp.weixin.qq.com/s/cMxZv1s2iFHgOsidC_rbAA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwS6DZvFFkicyiag9utmwsDDcfYKVU2QQas5eXgTzSf9HHEvNJHGLt51hIxXc8jWXqRPSdHroT9YtYEQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>B7-H3是“敌”是“友”？]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：CD47</title><link>https://mp.weixin.qq.com/s/l83RplruaMBwDQSh5p-FmQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfHAHexXQAssdxAWl1ksQNhXK7tf4iaIcibmUjIR2k5GBenyosWUMpllLtiajkp3fg8cO12pjR6gDXd6A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>CD47被广泛认为是一种“不要吃我”的信号]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：突破还是延续？</title><link>https://mp.weixin.qq.com/s/otrpNHNOZ4T4aAiozQDfVA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfEp9uphkA8dTZeETrGbGwUNsdtyFUGBegDtxDDsPh04vfked4pKvQNJYa3oZCJNaSR8pxN9xXAOdw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>新一代的免疫检查点抑制剂：突破还是延续？]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：临床挑战</title><link>https://mp.weixin.qq.com/s/hJSKlvwQZnnhBSigSs7Zsg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfEp9uphkA8dTZeETrGbGwUNM18CbEBRMRHYRV8zQ2AyM0mstGAIY6exLE2iccu6IY3fToiaJU9iamXTA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>IO药物的开发存在一些饱和信号：临床上测试的创新MOA相对较少，审批处于停滞状态，一些肿瘤适应症和靶点已经存在饱和。]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈TNFRSF之CD40</title><link>https://mp.weixin.qq.com/s/oYgi8slR7uzK20JKGQWh9g</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfHgCI457NxTeZLMRzjm9KBia8Q5glXYQb7ib8d7TfACRhJIKHtaiaMoexWERWxAtrqicY5K2GyyqACuSQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>CD40信号是单核细胞成熟过程的重要触发因素]]></content:encoded><pubDate>Mon, 01 Mar 2021 06:06:37 +0800</pubDate></item><item><title>小药谈TNFRSF之OX40</title><link>https://mp.weixin.qq.com/s/LG7d8FMu8sd4dg3EwmWzZg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfHgCI457NxTeZLMRzjm9KBia2ico3qgEXohGibnG677czrHSIkepWskVia3ZoxRkFWCGTibo2KVzv9r4FQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>OX40共刺激与针对抑制性受体如抗PD-1和抗PD-L1的免疫疗法结合使用是一种很有前途的策略。]]></content:encoded><pubDate>Mon, 01 Mar 2021 06:06:37 +0800</pubDate></item><item><title>小药谈TNFRSF之4-1BB</title><link>https://mp.weixin.qq.com/s/-jTt3Q3NBJfLc_3zM7_8MA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfHgCI457NxTeZLMRzjm9KBia16fMXCwe7iaQ9SStibgGyVSrzQAWicqsP4yFJ0ZcHJAA5xRCnBnSCQeeg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>抗4-1BB与CTLA4或/和PD-1抗体在多种癌症类型中的协同抗癌作用，为将抗4-1BB抗体应用于免疫检查点治疗以提高癌症治疗水平提供了很好的方向。]]></content:encoded><pubDate>Mon, 01 Mar 2021 06:06:37 +0800</pubDate></item><item><title>小药谈TNFRSF之GITR</title><link>https://mp.weixin.qq.com/s/STejSiZx0z9QAdCztEELTw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfHgCI457NxTeZLMRzjm9KBiaS3dQFSSHZoDRtyDVhrs72e5fCy5u9v8l11gvrc8pFFWYluFuzsaPRQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>触发GITR可增加CD8+和CD4+效应T细胞活性，减少肿瘤浸润Tregs。]]></content:encoded><pubDate>Mon, 01 Mar 2021 06:06:37 +0800</pubDate></item></channel></rss>